A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019)

References

• Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744–e757.
   PubMed Web of Science ®Google Scholar
• Unicef supply division/“pneumococcal conjugate vaccine: supply and deman update. Jul 2020. Available at: https://www.unicef.org/supply/sites/unicef.org.supply/files/2020-07/Pneumococcal-conjugate-vaccine-supply-update-July2020.pdfAccessed:August3,2020
   Google Scholar
• Chen JJ, Yuan L, Huang Z, et al. “Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.”. BMJ Open. 2016;6(10):e012488.
   PubMed Web of Science ®Google Scholar
• Kwambana-Adams BA, Kirkham L-A, Whitney C, et al. State-of-the-art in the pneumococcal field: Proceedings of the 11th international symposium on pneumococci and pneumococcal diseases (ISPPD-11). Pneumonia. 2020;12(1):2.
   Web of Science ®Google Scholar
• Onishchenko K, Hill S, Wasserman M, et al. “Trends in vaccine investment in middle income countries”. Hum Vaccin Immunother. 2019;15(10):2378–2385.
   PubMed Web of Science ®Google Scholar
• Boonacker CWB, Broos PH, Sanders EAM, et al. Rovers MM: Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children. PharmacoEconomics. 2011;29(3):199–211.
   PubMed Web of Science ®Google Scholar
• Isaacman DJ, Strutton DR, Kalpas EA, et al. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther. 2008;30(2):341–357.
   PubMed Web of Science ®Google Scholar
• Farkouh RA, Klok RM, Postma MJ, et al. Strutton DR: cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines. 2012;11(10):1235–1247.
   PubMed Web of Science ®Google Scholar
• McClure CA, Ford MW, Wilson JBAramini JJ. Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits. Can J Infect Dis Med Microbiol. 2006;17(1):19–26.
   PubMedGoogle Scholar
• Van De Vooren K, Duranti S, Curto A, et al. Cost effectiveness of the new pneumococcal vaccines: A systematic review of european studies. PharmacoEconomics. 2014;32(1):29–45.
   PubMed Web of Science ®Google Scholar
• Ray GT. Pneumococcal conjugate vaccine: review of cost–effectiveness studies in Australia, North America and Europe. Expert Rev Pharmacoecon Outcomes Res. 2008;8(4):373–393.
   PubMedGoogle Scholar
• Beutels P, Thiry N, Van Damme P. Convincing or confusing?: economic evaluations of childhood pneumococcal conjugate vaccination—a review (2002–2006). Vaccine. 2007;25(8):1355–1367.
   PubMed Web of Science ®Google Scholar
• Wu DB, Chaiyakunapruk N, Chong HY, et al. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014). Vaccine. 2015;33(14):1633–1658.
   PubMed Web of Science ®Google Scholar
• Saokaew S, Rayanakorn A, Wu DB-C, et al. Cost effectiveness of pneumococcal vaccination in children in low-and middle-income countries: a systematic review. Pharmacoeconomics. 2016;34(12):1211–1225. •• Our review drew from the Saokaew et al (2016), which is a systematic literature review of PCV economic evaluations until 2015, focused on low and middle income countries
   Google Scholar
• Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. ed. Oxford: Oxford University Press; 1997.
   Google Scholar
• Nakamura MM, Tasslimi A, Lieu TA, et al. “Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries”. Int Health. 2011;3(4):270–281.
   PubMed Web of Science ®Google Scholar
• Tasslimi A, Nakamura MM, Lieu TA, et al. “Cost effectiveness of child pneumococcal conjugate vaccination in GAVI-eligible countries”. Int Health. 2011;3(4):259–269.
   PubMed Web of Science ®Google Scholar
• Chen C, Liceras FC, Flasche S, et al., Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob Health. 7(1): e58–e67. 2019. .
   PubMed Web of Science ®Google Scholar
• Che D, Zhou H, He J, et al. “Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination”. BMC Health Serv Res. 2014;14(1):56.
   PubMed Web of Science ®Google Scholar
• Hu S, Shi Q, Chen C-I, et al. “Estimated public health impact of nationwide vaccination of infants with 7-valent pneumococcal conjugate vaccine (PCV7) in China”. Inter J Infect Dis. 2014;26:116–122.
   PubMed Web of Science ®Google Scholar
• Caldwell R, Roberts CS, An Z, et al. “The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China”. BMC Infect Dis. 2015;15(1):284.
   PubMedGoogle Scholar
• Maurer KA, Chen H-F, Wagner AL, et al. “Cost-effectiveness analysis of pneumococcal vaccination for infants in China”. Vaccine. 2016;34(50):6343–6349.
   PubMed Web of Science ®Google Scholar
• Mo X, Gai Tobe R, Liu X, et al. “Cost-effectiveness and health benefits of pediatric 23-valent pneumococcal polysaccharide vaccine, 7-valent pneumococcal conjugate vaccine and forecasting 13-valent pneumococcal conjugate vaccine in China”. Pediatr Infect Dis J. 2016;35(11):e353–e361.
   PubMed Web of Science ®Google Scholar
• Shen K, Wasserman M, Liu D, et al. “Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China”. PloS One. 2018;13(7):e0201245.
   PubMed Web of Science ®Google Scholar
• Zhou H, He J, Wu B, et al. “Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants”. Hum Vaccin Immunother. 2018;14(6):1444–1452.
   PubMed Web of Science ®Google Scholar
• Aljunid S, Abuduxike G, Ahmed Z, et al. “Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia”. BMC Infect Dis. 2011;11(1):248.
   PubMedGoogle Scholar
• Aljunid S, Maimaiti N, Ahmed Z, et al. “Economic impact of pneumococcal protein-D conjugate vaccine (PHiD-CV) on the Malaysian national immunization programme”. Value Health Reg Issues. 2014;3:146–155.
   PubMedGoogle Scholar
• Wang XJ, Saha A, Zhang X-H. “Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+ 1 schedule in Malaysia”. Cost Eff Resour Allocation. 2017;15(1):17.
   PubMedGoogle Scholar
• Wu D, Bin-Chia, Roberts C, Lee VWY, et al. “Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong”. Hum Vaccin Immunother. 2016;12(2):403–416.
   PubMed Web of Science ®Google Scholar
• Hoshi S-L, Kondo M, Okubo I. “Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan”. Vaccine. 2012;30(22):3320–3328.
   PubMed Web of Science ®Google Scholar
• Hoshi S-L, Kondo M, Okubo I. “Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan”. Vaccine. 2013;31(25):2762–2771.
   PubMed Web of Science ®Google Scholar
• Shiragami M, et al. “Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal vaccine in Japanese children”. Infect Dis Ther. 2015;4(1):93–112.
   Web of Science ®Google Scholar
• Lee KKC, Wu DB-C, Topachevskyi O, et al. The health economic impact of universal infant vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as compared with 13-valent pneumococcal conjugate vaccine in Hong Kong. Value Health Reg Issues. 2013;2(1):64–74.
   PubMedGoogle Scholar
• Lee KKC, Rinaldi F, Chan MK, et al. “Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong”. Value Health. 2009;12:S42–S48.
   PubMed Web of Science ®Google Scholar
• Sohn HS, Suh D-C, Jang E, et al. “Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea”. J Managed Care Pharm. 2010;16(1):32–45.
   Google Scholar
• Zhang X-H, Leeuwenkamp O, Oh K-B, et al. “Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea”. Hum Vaccin Immunother. 2018;14(1):85–94.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy Y, Eliyas SK, Nair NP, et al. Impact and cost effectiveness of pneumococcal conjugate vaccine in India. Vaccine. 2019;37(4):623–630.
   PubMed Web of Science ®Google Scholar
• Megiddo I, Klein E, Laxminarayan R. “Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India”. BMJ Glob Health. 2018;3(3):e000636.
   PubMed Web of Science ®Google Scholar
• Wu D, Bin-Chia,  Chang C-J, Huang Y-C, et al. “Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach”. Value Health. 2012;15(1):S15–S19.
   PubMed Web of Science ®Google Scholar
• Wu D, Chia B, Rinaldi F, Huang YC, et al. “Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness analysis”. J Formosan Med Assoc. 2013;112(3):151–160.
   PubMed Web of Science ®Google Scholar
• DilokthornsakulP, Kengkla K, Saokaew S, et al., An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine. 37(32): 4551–4560. 2019. .
   PubMed Web of Science ®Google Scholar
• Kulpeng W, Leelahavarong P, Rattanavipapong W, et al. “Cost-utility analysis of 10-and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?”. Vaccine. 2013;31(26):2839–2847.
   PubMed Web of Science ®Google Scholar
• Haasis MA, Ceria JA, Kulpeng W, et al. “Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines”. PloS One. 2015;10(7):e0131156.
   PubMed Web of Science ®Google Scholar
• Zhang X-H, Nievera MC, Carlos J, et al. “Cost-effectiveness analysis of pneumococcal vaccination with the pneumococcal polysaccharide NTHi protein D conjugate vaccine in the Philippines”. Value Health Reg Issues. 2014;3:156–166.
   PubMedGoogle Scholar
• Tyo KR, Rosen MM, Zeng W, et al. “Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines”. Vaccine. 2011;29(38):6686–6694.
   PubMed Web of Science ®Google Scholar
• Sundaram N, Chen C, Yoong J, et al. “Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia”. Vaccine. 2017;35(7):1055–1063.
   PubMed Web of Science ®Google Scholar
• Dorji K, Phuntsho S, Kumluang S, et al. “Towards the introduction of pneumococcal conjugate vaccines in Bhutan: a cost-utility analysis to determine the optimal policy option”. Vaccine. 2018;36(13):1757–1765.
   PubMed Web of Science ®Google Scholar
• Farkouh RA, Hall-Murray C, Klok RM, et al. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable haemophilus influenzae protein d conjugate vaccine and 13-valent pneumococcal vaccine in japanese children. Infect Dis Ther. 2015 Jun. 4(2):227–233. Epub 2015 Apr 24 . Comment on:
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children—a population-based study. PLoS One. 2015;10(3):e0120290.
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2(6):464–471.
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Serres G, Boulianne N, et al. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine 2015;33(23):2684–2689.
   PubMed Web of Science ®Google Scholar
• Isturiz R, Sings HL, Hilton B, et al. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017;16(10):1007–1027.
   PubMed Web of Science ®Google Scholar
• De Melker HE, Sanders EA, van der Ende A., editors. Incidence of IPD in the Netherlands up to five years after introduction of PCV102016: national Institute for Public Health and the Environment
   Google Scholar
• Brandileone MC, Almeida SCG, Minamisava R, et al. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of ten-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018;36(19):2559–2566.
   PubMed Web of Science ®Google Scholar
• Belgium Superior Health Council. Infant Pneumococcal Vaccination 2018 [Dec 2018]. Available from: https://www.health.belgium.be/en/node/34692.
   Google Scholar
• Htar TT, Myint, Sings HL, Syrochkina M, et al. “The impact of pneumococcal conjugate vaccines on serotype 19A nasopharyngeal carriage.”. Expert Rev Vaccines. 2019;18(12):1243–1270.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Seppä I, et al. Effectiveness of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D–conjugated vaccine (PHiD-CV) against carriage and acute otitis media—a double-blind randomized clinical trial in Finland. J Pediatric Infect Dis Soc. 2016;5(3):237–248.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Castrejon M, Rowley S, et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against acute otitis media in children in Panama. Poster presentation. The 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR) March 13–15, Kuala Lumpur, Malaysia.
   Google Scholar
• Prymula R, Irena H, Miroslav S, et al. Impact of the 10-valent pneumococcal nontypeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine. 2011;29(10):1959–1967 . PMID:21215830
   PubMed Web of Science ®Google Scholar
• Best EJ, Walls T, Souter M, et al. Pneumococcal vaccine impact on otitis media microbiology: a New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine. Vaccine. 2016;34(33):3840–3847.
   PubMed Web of Science ®Google Scholar
• Leach AJ, Wigger C, Hare K, et al. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine. BMC Pediatr. 2015;15(1):162.
   PubMedGoogle Scholar
• Van Den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D–conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2012;56(3):e30–e39.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Sáez-Llorens X, López P, et al. Efficacy of pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657.
   PubMed Web of Science ®Google Scholar
• Delgleize E, Leeuwenkamp O, Theodorou E, et al. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. BMJ Open. 2016;6(11):e010776.
   PubMed Web of Science ®Google Scholar
• Gómez JA, Villaseñor-Sierra A, Aguilar GM, et al. Estimación de la relación costo-efectividad de las vacunas neumocócicas conjugadas Prevenar-13 y Synflorix®, utilizadas en los programas de vacunación de población infantil Mexicana. Value Health Reg Issues. 2016;11:76–84.
   PubMedGoogle Scholar
• Castiglia P, Pradelli L, Castagna S, et al. Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy. Hum Vaccin Immunother. 2017;13(10):1–9.
   Web of Science ®Google Scholar
• Talbird SE, Taylor TN, Knoll S, et al. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010;28(Suppl 6):G23–G29.
   PubMedGoogle Scholar
• Knerer G, Ismaila A, Pearce D. Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J Med Econ. 2012;15(1):61–76.
   PubMedGoogle Scholar
• By A, Sobocki P, Forsgren A, et al. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther. 2012;34(1):177–189.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. Minutes of the JCVI pneumococcal subcommittee meeting, 2012 May 30. http://webarchive.nationalarchives.gov.uk/20130402145952/http:/transparency.dh.gov.uk/2012/07/27/jcvipneumococcal-sub-committee-meeting-may-2012/
   Google Scholar
• Joint Committee on Vaccination and Immunisation. Minutes of the JCVI meeting, 2014Jun4. https://app.box.com/s/iddfb4ppwkmtjusir2tc#/s/iddfb4ppwkmtjusir2tc/1/2199012147/19052160649/1?&_suid=142195891623007725862911282104.
   Google Scholar
• Moore MR Update on effectiveness and impact of PCV13 use among U.S. children. [cited 2015 Jan 21]. Available from: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-02/02-Pneumo-Moore.pdf.AccessedJan21,2015.
   Google Scholar
• Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011. Pediatr Infect Dis J. 2013;32(6):656–661.
   PubMed Web of Science ®Google Scholar
• Van Der Linden M, Weiss S, Falkenhorst G, et al. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 2012;30(40):5880–5885.
   PubMed Web of Science ®Google Scholar
• Sings HL, De Wals P, Gessner BD, et al. “Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies”. Clinl Infect Dis. 2019;68(12):2135–2143.
   PubMed Web of Science ®Google Scholar
• Hu S, Shi Q, Song S, et al. “Estimating the cost-effectiveness of the 7-valent pneumococcal conjugate vaccine in Shanghai, China”. Value Health Reg Issues. 2014;3:197–204.
   PubMedGoogle Scholar